For the quarter ending 2026-03-31, ANIP has $1,421,970K in assets. $859,670K in debts. $311,176K in cash and cash equivalents.
| Balance Sheets | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Cash and cash equivalents | 311,176 | 285,585 | 262,610 | 217,797 |
| Restricted cash | 36 | 36 | 36 | 36 |
| Accounts receivable, net | 255,432 | 281,082 | 252,617 | 225,654 |
| Inventories | 143,468 | 143,067 | 146,475 | 138,315 |
| Prepaid income taxes | - | 11,027 | 9,254 | - |
| Prepaid expenses and other current assets | 22,087 | 23,189 | 18,551 | 15,110 |
| Investment in equity securities | 14,885 | 9,131 | 8,859 | 5,718 |
| Total current assets | 747,084 | 753,117 | 698,402 | 602,630 |
| Property and equipment, net | 67,115 | 62,476 | 63,560 | 59,247 |
| Deferred tax assets, net | 66,555 | 69,072 | 71,396 | 92,025 |
| Total | - | - | 499,817 | - |
| Gross carrying amount-In Process Research And Development | - | - | 0 | - |
| Intangible assets, net | 467,161 | 479,526 | 499,817 | 520,320 |
| Goodwill | 62,480 | 62,480 | 62,480 | 60,533 |
| Other non-current assets | 11,575 | 13,706 | 12,497 | 8,246 |
| Total assets | 1,421,970 | 1,440,377 | 1,408,152 | 1,343,001 |
| Current debt, net | 19,298 | 17,268 | 15,241 | 13,216 |
| Current contingent consideration | - | 167 | 63 | 483 |
| Accounts payable | 69,694 | 62,583 | 69,795 | 54,569 |
| Accrued royalties | 33,926 | 48,497 | 51,247 | 36,030 |
| Accrued compensation and related expenses | 16,091 | 37,897 | 33,221 | 32,933 |
| Accrued government rebates | 38,417 | 43,154 | 37,032 | 32,866 |
| Income taxes payable | 5,297 | 1,291 | 0 | 3,294 |
| Income taxes payable - foreign | - | 948 | - | - |
| Returned goods reserve | 43,052 | 49,504 | 50,005 | 48,683 |
| Accrued expenses and other | 13,735 | 16,803 | 13,951 | 14,761 |
| Total current liabilities | 239,510 | 278,112 | 270,555 | 236,835 |
| Debt, net | 285,996 | 291,840 | 297,677 | 301,484 |
| Convertible notes, net | 308,466 | 307,927 | 307,392 | 306,862 |
| Accrued licensor payments due | - | 0 | 4,062 | 11,428 |
| Contingent consideration, net | 9,248 | 9,610 | 11,379 | 18,089 |
| Other non-current liabilities | 16,450 | 12,164 | 11,270 | 6,696 |
| Total liabilities | 859,670 | 899,653 | 902,335 | 881,394 |
| Common stock, 0.0001 par value, 66,000,000 shares authorized 23,758,658 shares issued and 22,877,168 outstanding at march31, 2026 23,112,577 shares issued and 22,491,281 shares outstanding at december31, 2025 | 3 | 3 | 3 | 2 |
| Treasury stock, 881,490 shares of common stock, at cost, at march31, 2026 and 621,296 shares of common stock, at cost, at december31, 2025 | 53,004 | 33,249 | 32,638 | 31,594 |
| Additional paid-in capital | 608,429 | 596,036 | 586,230 | 541,899 |
| Retained earnings (accumulated deficit) | 6,393 | -23,099 | -50,589 | -76,862 |
| Accumulated other comprehensive income, net of tax | 479 | 1,033 | 2,811 | 3,312 |
| Total stockholders equity | 562,300 | 540,724 | 505,817 | 436,757 |
| Convertible preferred stock, series a, 0.0001 par value, 1,666,667 shares authorized 25,000 shares issued and outstanding at june30, 2025 and december31, 2024 | - | - | - | 24,850 |
| Total liabilities and stockholders equity | 1,421,970 | 1,440,377 | 1,408,152 | 1,343,001 |
ANI PHARMACEUTICALS INC (ANIP)
ANI PHARMACEUTICALS INC (ANIP)